Ads
related to: treatment for macular degeneration- Clinical Trial Data
View Clinical Trial Data On Safety
Of A DME Treatment
- Patient Financial Support
Help Your Patients Reduce Their
Financial Burden For Treatment
- HCP Resources
Find HCP & Practice Resources
For Viewing Or Download
- Dosing Information
See The Dosing Options And Schedule
For A Wet AMD Treatment
- Safety Information
Find ISI & Prescribing Info For A
Wet AMD And DME Treatment
- Mechanism Of Action
View The Proposed MOA For An FDA
Approved Therapy For nAMD & DME
- Clinical Trial Data
Search results
Results from the WOW.Com Content Network
The FDA approved two biosimilars for Eylea (aflibercept), a drug used to treat age-related macular degeneration, diabetic retinopathy and other eye conditions. Biosimilars Yesafili and Opuviz work ...
8.7% global prevalence in 2020 [2] Macular degeneration, also known as age-related macular degeneration ( AMD or ARMD ), is a medical condition which may result in blurred or no vision in the center of the visual field. [1] Early on there are often no symptoms. [1] Over time, however, some people experience a gradual worsening of vision that ...
Stem cell therapy for macular degeneration is the use of stem cells to heal, replace dead or damaged cells of the macula in the retina. Stem cell based therapies using bone marrow stem cells as well as retinal pigment epithelial transplantation are being studied. [1] A number of trials have occurred in humans with encouraging results.
Anti–vascular endothelial growth factor therapy, also known as anti-VEGF ( / vɛdʒˈɛf /) therapy or medication, is the use of medications that block vascular endothelial growth factor. This is done in the treatment of certain cancers and in age-related macular degeneration. They can involve monoclonal antibodies such as bevacizumab ...
Macular degeneration happens with age, when the macula, at the center of the retina — “the part of the eye that sees the world for us,” Dr. Vlad Diaconita, a retinal and vitreoretinal ...
Aflibercept. Aflibercept, sold under the brand names Eylea among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [10] [11] It was developed by Regeneron Pharmaceuticals . It is an inhibitor of vascular endothelial growth factor (VEGF).
Ads
related to: treatment for macular degeneration